Table 2.
Associated factors to flare after SARS-COV-2 immunization
| Flare | No flare | P valuea | RR-IC | |
|---|---|---|---|---|
|
Age, years Median (IQR) |
37 (28–43.5) |
35 (27.5–51) |
0.945 | – |
| Sex | ||||
| Male | 2 (33.3%) | 4 (66.7%) | 0.597 | – |
| Female | 18 (19.2%) | 76 (80.8%) | ||
|
Time of illness, years Median (IQR) |
5 (3.5–10.5) | 8 (4–14) | 0.218 | – |
| Comorbidities | 13 (23.6%) | 42 (76.4%) | 0.315 | – |
| Systematic commitment to SLE | ||||
| Articular | 15 (20.3%) | 59 (79.7%) | 0.909 | – |
| Renal | 8 (13.3%) | 52 (86.7%) | <0.001b | 0.38 (0.15–0.91) |
| Dermatological | 6 (26.1%) | 17 (73.9%) | 0.391 | – |
| Hematological | 7 (33.3%) | 14 (66.7%) | 0.122 | – |
| Mucocutaneous | 5 (29.4%) | 12 (70.6%) | 0.322 | – |
| Pulmonary | 3(20%) | 12 (80%) | 1 | – |
| Neurological | 3 (20%) | 12 (80%) | 1 | – |
| Cardiovascular | 1 (25%) | 3 (75%) | 1 | – |
| Regular treatment for SLE | ||||
| No treatment | 3 (33.3%) | 6 (66.7%) | 0.378 | – |
| Hydroxychloroquine | 11 (14.7%) | 64(85.3%) | <0.001b | 0.20 (0.06–0.63) |
| Prednisone | 16 (22.5%) | 55 (77.5%) | 0.321 | – |
| Azathioprine | 10 (41.7%) | 14 (58.3%) | <0.001b | 7.96 (2.70–23.43) |
| Mycophenolate | 3 (13%) | 20 (87%) | 0.553 | – |
| Methotrexate | 3 (37.5%) | 5 (62.5%) | 0.196 | – |
| Cyclophosphamide | 0 | 5 (100%) | – | – |
| COVID-19 background | 13 (33.3%) | 26 (66.7%) | <0.001b | 1.68 (0.69–4.09) |
| Flare within 6 months prior to immunization | 8 (28.6%) | 20 (71.4%) | 0.181 | – |
aP value <0·05 indicates statistical significance at 95% confidence interval
bPoisson regression analysis, for a P value adjusted for age, sex, treatment use, history of confirmed COVID-19 and renal involvement, with 95% confidence interval